What we say about the firm's legal practice in United States
Litigation
Within Product liability and mass tort defense: pharmaceuticals and medical devices, Pepper Hamilton LLP is a third tier firm,
Pepper Hamilton LLP’s Philadelphia-based practice has a strong track record of success in health effects litigation and is regularly instructed by pharmaceutical, medical device and biotech companies. One of its strengths is the ability to adapt different strategies to meet client needs, whether through settlement, pre-trial dismissals or courtroom victories. The firm serves as national counsel to Eli Lilly and represented it in a Congressional hearing on the Zyprexa cases. The team negotiated a $1.4bn settlement with Pennsylvania state attorneys and Medicaid lawyers, among a number of other settlements reached with state attorneys general and, overall, the firm has settled or dismissed before trial more than 31,000 Zyprexa cases. Other successes for the same client included obtaining a significant judgment in federal court in the Eastern District of New York pertaining to Mississippi’s case seeking restitution for Medicaid expenses relating to Zyprexa, which was dismissed on summary judgment although plaintiffs appealed against one aspect of the verdict. The firm is also a trusted adviser to GlaxoSmithKline, for which it serves as national counsel for litigation relating to Avandia diabetes treatment, a 15,000-case MDL with coordinated actions in California. Other clients include the American Red Cross, CB Fleet and Medtronic. Practice head Nina Gussack is highly recommended.